Market Snapshot
Key Players
Inc (U.S.)
SciGene Corporation (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Agilent Technologies
Inc. (U.S.)
Yikon Genomics (U.S.)
Global Statistics Representing Preimplantation Genetic Testing Market Scenario
Breakthrough advancements in embryo culture, freezing egg technologies and DNA analysis has favored the use of IVF. Moreover, IVF and Preimplantation genetic testing (PGT) are providing new meaning to family planning across the globe. PGT is used as a screening test to determine genetic or chromosomal anomalies in embryos during In vitro fertilization (IVF). Apart from this, it also aids in eliminating genetic disorders. Besides, 1 in every 33 babies in the U.S. are affected by birth defects annually, CDC.
Increasing application of IVF procedures as a result of infertility in women and men around the world is boosting the market growth. Polycystic ovarian syndrome (PCOS) is one of the most common cause for female infertility, and over 6.1 million women are suffering from it, the U.S. Department of Health and Human Services. In addition, excessive smoking and chewing of tobacco are causing infertility in women to some extent.
Birth success rates in IVF procedures is also presenting strong multitudes of growth trends. According to CDC, over 1.5% of babies in the U.S. are conceived through assisted reproductive technology (ART) every year. In addition, in 2017, there were 690 treatment cycles of PGD were performed, out of which 90 cycles used fresh embryo and 600 used frozen embryos.
The Global preimplantation genetic testing market is expected to reach USD 465.1 million by 2026 at a CAGR of 8.7% during the forecast period of 2019–2026.
Segmental Insight
In this study, we have segmented the global preimplantation genetic testing market by procedure type, application, technology, product & service, and end-user.
By technology, the preimplantation genetic testing market is segmented into NGS, PCR, FISH, CGH, and SNP. The next-generation sequencing (NGS) is projected to hold the largest share during the forecast period. This can be attributed to increasing single gene diseases. Besides, over 350 million people are suffering from rare diseases worldwide, the Global Genes Organization. Moreover, Illuminas is a NGS platform widely used for genome sequencing, analysis of epigenetic factors, and single mutations.
By application, aneuploidy screening is accounted for the highest revenue. Increasing birth defects among the expecting mothers in developed economies are the prime contributors to the market growth. In addition, over 6,000 babies in the U.S are born with down syndrome, the National Down Syndrome Society.
Regional Insight
The Global preimplantation genetic testing market is segmented by the Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is expected to dominate the market and the U.S. is likely to emerge as the major contributor to regional growth. According to CDC, over 6.1 million women and 9% of men in the U.S. are barren. However, technologically advanced infertility treatments have helped thousands of couples to experience parenthood. Currently, over 1.5% of babies are conceived using an ART in the U.S. each year. Moreover, the U.S. has around 440 clinics providing services for infertility and infertility insurance coverage as IVF is an expensive procedure.
In Canada, over 16% of the couples are suffering from infertility, and there were 15,344 cycles of IVF being initiated, the Canadian Fertility & Andrology Society.
Europe is the second leading region in the global preimplantation genetic testing market and is likely to continue the same during the forecast period. From the last few years, the birth rate has been dropping in Europe, which is compelling the couples to go through assisted reproductive technologies (ART). Over 50% of all treatment cycles are conducted in the region. Moreover, the Nordic countries and Belgium have the highest ART availability in terms of cycles per million population, the European Society of Human Reproduction and Embryology. Increasing maternal age and miscarriages are two complication for pregnancy and can lead to serious health issues. For instance, 1 in every 100 women in the UK experiences recurrent miscarriages, the Tommy’s Organization. Thus, In vitro fertilization (IVF) and preimplantation genetic diagnosis (PGD) are now well-established treatments, which is being provided in many European countries. In 2016, Spain was the topmost country in assisted reproduction, with a record of 140,909 treatment cycles performed, followed by Russia (121,235 cycles), France (104,733), and Germany (969,226), ESHRE.
Key Players
Some of the prominent players in the global preimplantation genetic testing market are Illumina, Inc (U.S.), SciGene Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Yikon Genomics (U.S.), Oxford Gene Technology (UK), Rubicon Genomics, Inc. (U.S.), Natera, Inc. (U.S.), Abbott (U.S.), CooperSurgical, Inc (U.S.), and PerkinElmer Inc (U.S.).
Intended Audience
- Fertility Clinics and Maternity Centers
- Preimplantation Genetic Diagnosis and Screening Manufacturers, CMOs, CROs
- Potential Investors
- Government agencies
- Research and Academic Institutes
Our Report Covers
- Historical inferences, conclusions & analysis of the market from 2016 to 2018
- Projections and performance forecast analysis for the future from 2019-2026
- Production and consumption point of view (POV) analysis
- Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
- Comprehensive competitive landforms mapping with recent development covering market leadership, competency, sustainability, and prospects
Preimplantation Genetic Testing Market Segmentation
By Procedure Type
- Preimplantation Genetic Screening
- Preimplantation Genetic Diagnosis
By Technology
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Fluorescence in Situ Hybridization
- Comparative Genomic Hybridization
- Single-Nucleotide Polymorphism
By Product and Service
- Reagents and Consumables
- Instruments
- Software and Services
By Application
- Aneuploidy Screening
- Structural Chromosomal Abnormalities
- Translocations
- Deletions
- Duplications
- Inversions
- X-Linked Disorders
- HLA Typing
- Single Gene Disorder Screening
- Gender Identification
By End User
- Hospitals
- Diagnostic Laboratories
- Research & Academic Centers
- Fertility Clinics & Maternity Centers
Regions Covered
America
- North America
- U.S.
- Canada
- Mexico
- South America
Europe
- Western Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Eastern Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
MEA
- The Middle East
- Saudi Arabia
- UAE
- Qatar
- Rest of The Middle East
- Africa
Key Players
Illumina, Inc.
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
SciGene Corporation
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
Thermo Fisher Scientific Inc.
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
Agilent Technologies, Inc.
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
Yikon Genomics
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
Oxford Gene Technology
- Company Overview
- Performance
- Recent Developments
- Product Portfolio
Rubicon Genomics, Inc.
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
Natera, Inc.
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
Abbott
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
CooperSurgical, Inc.
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
PerkinElmer Inc
- Company Overview
- Financial Performance
- Recent Developments
- Product Portfolio
